<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="211">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400242</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-MM-200</org_study_id>
    <nct_id>NCT02400242</nct_id>
  </id_info>
  <brief_title>Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma</brief_title>
  <official_title>A Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Antitumor Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acetylon Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acetylon Pharmaceuticals Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1a/1b, multicenter, single-arm, open-label, dose escalation study to
      determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary antitumor
      activity of ACY-241 for oral administration as monotherapy and in combination therapy with
      orally administered pomalidomide and low-dose dexamethasone in eligible patients with
      relapsed or relapsed-and-refractory multiple myeloma (MM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During phase 1a, patients will receive 1 cycle of ACY-241 monotherapy. Patients who complete
      the ACY-241 monotherapy cycle without a dose limiting toxicity (DLT) and are clinically
      stable may continue to phase 1b combination therapy, beginning with Cycle 2. During phase
      1b, patients will receive ACY 241 in combination with pomalidomide and low dose
      dexamethasone at the currently approved pomalidomide dose and schedule. Each cohort of
      patients in phase 1a and phase 1b will consist of at least 3 patients. The first patient
      enrolled in each cohort of phase 1a will be observed for 1 week before enrollment of
      subsequent patients in the cohort. Patients who withdraw consent before entering phase 1b
      will be replaced. (Replacement patients must complete phase 1a prior to continuing to phase
      1b.) Patients who experience a DLT or other unacceptable toxicity in Cycle 1 of phase 1a
      monotherapy or Cycle 2, the first cycle of phase 1b combination therapy, will be removed
      from study treatment. An assessment of the safety of treatment will be completed by the
      Safety Review Committee (SRC) prior to dose-escalation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maximum tolerated dose of ACY-241 as monotherapy as assessed by dose limiting toxicities</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of ACY-241 in combination with pomalidomide and low dose dexamethasone as assessed by dose limiting toxicities</measure>
    <time_frame>Cycle 2 (28 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>First cycle of combination therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of AEs as measured by safety and tolerability</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single- and multiple-dose peak-plasma concentration</measure>
    <time_frame>Cycle 1 days 1, 2, 15 and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single- and multiple-dose area under the plasma concentration versus time curve</measure>
    <time_frame>Cycle 1 days 1, 2, 15 and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in acetylation of histone and tubulin as a measure of pharmacodynamics</measure>
    <time_frame>Cycles 1 days 1, 2, 15, 16 and 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fetal hemoglobin expression as a measure of pharmacodynamics</measure>
    <time_frame>Cycles 1 days 1, 2, 15, 16 and 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACY-241 metabolite concentration in blood samples</measure>
    <time_frame>Cycles 1 days 1, 2, 15, 16 and 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure response analyses of potential biomarkers of response.</measure>
    <time_frame>Cycles 1 days 1, 2, 15, 16 and 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of AEs as measured by safety and tolerability in combination</measure>
    <time_frame>Beginning at Cycle 2 (28 day cycle each) until end of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fetal hemoglobin expression as a measure of pharmacodynamics</measure>
    <time_frame>Cycle 2 days 1, 2, 15, 16 and 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in acetylation of histone and tubulin as a measure of pharmacodynamics</measure>
    <time_frame>Cycle 2 days 1, 2, 15, 16 and 22</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single- and multiple-dose area under the plasma concentration versus time curve</measure>
    <time_frame>Cycle 2 days 1, 2, 15, and 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of M-protein as a measure of anti-tumor activity</measure>
    <time_frame>Day 1 of each cycle beginning at Cycle 2</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ACY-241, Pomalidomide, and dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACY-241</intervention_name>
    <description>Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.</description>
    <arm_group_label>ACY-241, Pomalidomide, and dexamethasone</arm_group_label>
    <other_name>Histone deacetylase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>4 mg qd dosed on days 1-21 of a 28 day cycle</description>
    <arm_group_label>ACY-241, Pomalidomide, and dexamethasone</arm_group_label>
    <other_name>immunomodulatory agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg qd on days 1, 8, 15, 22</description>
    <arm_group_label>ACY-241, Pomalidomide, and dexamethasone</arm_group_label>
    <other_name>corticosteriod</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Must have a documented diagnosis of MM and have relapsed or relapsed-and-refractory
             disease. All patients must have relapsed after having achieved at least stable
             disease (SD) for at least 1 cycle of treatment to at least 1 prior regimen and then
             developed progressive disease (PD). Relapsed-and-refractory patients also have
             documented evidence of PD during or within 60 days of completing last treatment

          -  Must have undergone prior treatment with at least 2 cycles of lenalidomide and at
             least 2 cycles of proteasome inhibitor unless not a candidate.

          -  May have undergone prior treatment with pomalidomide if patient is not refractory to
             pomalidomide and has previously achieved a response of MR or better to pomalidomide.

          -  Must have measurable disease (serum M-protein or urine M-protein).

          -  Must have Eastern Cooperative Oncology Group (ECOG) Performance score of 0, 1, or 2.

          -  Must be able to take low-dose aspirin, low molecular weight heparin, or other
             equivalent antithrombotic or anticoagulant daily as prophylactic anticoagulation.

        Key Exclusion Criteria:

          -  Prior therapy with pomalidomide with best response of PD or SD.

          -  Prior therapy with histone deacetylase (HDAC) inhibitor.

          -  Any of the following laboratory abnormalities: Absolute neutrophil count(ANC) &lt;
             1,000/µL, Platelet count &lt; 75,000/µL or &lt; 50,000/µL for patients in whom ≥ 50% of
             bone marrow nucleated cells are plasma cells, Hemoglobin &lt; 8 g/dL, Creatinine
             clearance &lt; 45 mL/min according to Cockcroft-Gault formula. If creatinine clearance
             calculated from the 24 hour urine sample is ≥ 45 mL/min, patient will qualify for the
             trial, Aspartate transaminase (AST) or Alanine transaminase (ALT) &gt; 3.0 × Upper
             Limited Normal (ULN), Serum total bilirubin &gt; 2.0 mg/dL or &gt; 3.0 × ULN for patients
             with hereditary benign hyperbilirubinaemia.

          -  Hematologic growth factors are not allowed at screening or during the first cycle of
             phase 1a or 1b.

          -  Nonsecretory myeloma or free light chain detected in serum only (ogliosecretory).

          -  Hypersensitivity to thalidomide, lenalidomide, pomalidomide, or dexamethasone

          -  Patients who received an allogeneic bone marrow or allogeneic peripheral blood stem
             cell transplant less than 12 months prior to initiation of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruben Niesvizky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa M Smith</last_name>
    <phone>617-245-1332</phone>
    <email>lsmith@acetylon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikolaus Trede, MD, PhD</last_name>
    <phone>617-245-1329</phone>
    <email>ntrede@acetylon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>8719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phyllis Schneider, RN</last_name>
    </contact>
    <investigator>
      <last_name>Amit Agarwal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Instittute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Murphy</last_name>
      <phone>720-754-4890</phone>
      <email>Juli.Murphy@HealthONECares.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Matous, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Dinh</last_name>
      <phone>305-243-9899</phone>
      <email>ytd3@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>James Hoffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Winship Cancer Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sagar Lonial, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Noopur Raj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul Richardson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rueben Niesvizky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Steven Weitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Odom, RN</last_name>
      <phone>206-386-3490</phone>
      <email>erin.odom@swedish.org</email>
    </contact>
    <investigator>
      <last_name>John Pagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Thierry Facon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Philippe Moreau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michel Attal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik, Abt. Innere Medizin V</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc-Steffen Raab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Athens School of Medicine</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ioannis Panagiotidis</last_name>
      <phone>+30 210 3381548</phone>
      <email>ionpanagiotidis@googlemail.com</email>
    </contact>
    <investigator>
      <last_name>Evangelos Terpos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedialiera San Giovanni Battista di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonella Bono</last_name>
      <email>antonella_bono@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Pallumbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Navarra</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>&quot;Jose I Gonzalez Rodroguez</last_name>
      <email>jgonzalezr@unav.es</email>
    </contact>
    <investigator>
      <last_name>Jesus San Miguel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fatima Mendez Ambel</last_name>
      <email>fmendezambel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Victoria Mateos Manteca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>April 13, 2016</lastchanged_date>
  <firstreceived_date>March 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
